Orion Oyj Class B ORNBV

Orion Oyj stock closed at €95.95 on 28 October, capping a strong run over the past quarter, just as Q3 2026 numbers landed. The headline is simple. Earnings kept tracking higher while the valuation still sits on a P/E of 20.4x that compares to a higher European pharmaceuticals industry average and much richer peers. Short term traders are reacting to a good quarter. Long term investors are staring at a different picture, one where a discounted cash flow estimate of €218.01 and a 30.3% net...

ORION CORPORATION INTERIM REPORT 1–9/2026 28 OCTOBER 2026 at 12:00 EET Orion Group Interim report January–September 2026: Strong financial performance and positive developments in the R&D pipeline July–September 2026 Highlights Net sales totalled EUR 542.2 (July–September 2025: 423.2) million Operating profit was EUR 209.9 (121.0) millionBasic earnings per share were EUR 1.19 (0.68)Cash flow from operating activities per share was EUR 0.68 (0.55)Phase 1 initiated with ODM-216, Orion's first biol

Interim Phase 3 data around darolutamide has put Orion Oyj (HLSE:ORNBV) back in focus, with investors weighing fresh oncology trial results, upgraded 2026 guidance and an upcoming reshuffle of the executive team. The recent Phase 3 darolutamide update and upgraded 2026 guidance have landed against a backdrop of strong momentum in Orion Oyj's shares. A 1 day share price return of 4.39% and a 30 day share price return of 16.15% support a year to date share price return of 52.21%. The 3 year...

Photo: Henri Salokangas Photo: Henri Salokangas ORION CORPORATION STOCK EXCHANGE RELEASE - CHANGES BOARD/MANAGEMENT/AUDITORS 26 October 2026 at 13.00 EET Changes in Orion Group’s Executive Team as of 1 January 2027 To accelerate the implementation of its strategy and support its next phase of growth, Orion Corporation (“Orion”) is adjusting the composition and responsibilities of its executive team as of 1 January 2027. The key changes are: A new International Commercial Operations organisation

ORION CORPORATION PRESS RELEASE 24 OCTOBER 2026 at 9.35 EEST Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence Interim analysis results from the Phase 3 trial DASL-HiCaP show a 58% reduction in the risk of metastasis or death in the combined primary endpoint of metastasis-free survival (MFS-CI) with darolutamide versus placebo, in addition to androgen deprivation therapy (ADT) and radiation therapy Four-y

ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION 20 OCTOBER 2026 at 20.20 EEST Inside information: Orion upgrades full-year outlook for 2026 Orion Corporation upgrades the full-year outlook for 2026 both for the part regarding net sales and operating profit. Orion’s royalty income has increased faster than expected during the first nine months of 2026, and this good development is anticipated to continue during the remainder of the year. Due to this reason, Orion upgrades the full-y

ORION CORPORATION PRESS RELEASE 14 OCTOBER 2026 at 9.00 EEST Orion publishes Interim Report for January–September 2026 and holds a webcast on 28 October 2026 Orion will publish Interim Report for January–September 2026 on Wednesday, 28 October 2026 at approximately 12.00 noon EET. The report and related presentation material will be available on the company’s website at www.orionpharma.com/investors after publishing. Webcast and conference call A webcast and a conference call for analysts, inves

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 7 OCTOBER 2026 at 9.00 EEST 125,000 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 125,000 A shares have been converted into 125,000 B shares. The conversion has been entered into the Trade Register on 7 October 2026. The total number of shares in Orion Corporation is 141,134,278 which, after the conver

ORION CORPORATION PRESS RELEASE 6 OCTOBER 2026 at 9.00 EEST Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market Orion Corporation (“Orion Pharma”) and Qilu Pharma Europe (“Qilu”) have entered into an agreement to commercialise intravenous (IV) pembrolizumab biosimilar in Europe. Pembrolizumab is an immune checkpoint inhibitor which is used to treat various cancers. Qilu is currently developing IV pembrolizumab. Under the terms of the agreemen

ORION CORPORATION PRESS RELEASE 05 OCTOBER 2026 at 8:00am ET Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing Milestone marks Orion Pharma’s entry into clinical-stage biologics (large molecules) and advances the company’s immuno-oncology portfolio ESPOO, Finland, CAMBRIDGE, United Kingdom and CAMBRIDGE, M.A., October 5, 2026 – Orion Corporation (Orion Pharma) today announced that the first patient

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE30 SEPTEMBER 2026 at 9.05 EEST Orion Corporation completed share acquisitions The share acquisitions announced by Orion Corporation on 27 August 2026 have been completed. The Company has purchased during the time period from 1 September 2026 to 29 September 2026 through trading on regulated market organised by Nasdaq Helsinki Oy a total of 500,000 Company's own B shares at an average pric

ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES IN COMPANY’S OWN SHARES30/09/2026 at 09.00 EEST Orion Corporation: Acquisition of own shares during week 40, 2026 The share buybacks form part of the share buyback programme that Orion Corporation announced on 27 August 2026. The buyback programme runs from 1 September 2026 until no later than 31 December 2026, and it is executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5 and the Commission

Orion Oyj (HLSE:ORNBV) has drawn attention after recent share price moves, with the stock last closing at €82.95. Investors are weighing that level against its historical returns and current valuation signals. Recent trading has built on earlier gains, with a 30-day share price return of 3.56% contributing to an 18.50% move over 90 days and a 31.04% year to date rise. Orion Oyj’s 1-year and 5-year total shareholder returns of 33.49% and 184.79% respectively show how recent momentum fits into...

Orion Corporation: Acquisition of own shares during week 39, 2026 The share buybacks form part of the share buyback programme that Orion Corporation announced on 27 August 2026. The buyback programme runs from 1 September 2026 until no later than 31 December 2026, and it is executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5 and the Commission Delegated Regulation (EU) 2016/1052. Orion Corporation’s shares have been acquired as follows: Date

ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES IN COMPANY’S OWN SHARES18/09/2026 at 19.00 EEST Orion Corporation: Acquisition of own shares during week 38, 2026 The share buybacks form part of the share buyback programme that Orion Corporation announced on 27 August 2026. The buyback programme runs from 1 September 2026 until no later than 31 December 2026, and it is executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5 and the Commission

Orion Corporation: Acquisition of own shares during week 37, 2026 The share buybacks form part of the share buyback programme that Orion Corporation announced on 27 August 2026. The buyback programme runs from 1 September 2026 until no later than 31 December 2026, and it is executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5 and the Commission Delegated Regulation (EU) 2016/1052. Orion Corporation’s shares have been acquired as follows: Date

ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES IN COMPANY’S OWN SHARES4 September 2026 at 19.00 EEST Orion Corporation: Acquisition of own shares during week 36, 2026 The share buybacks form part of the share buyback programme that Orion Corporation announced on 27 August 2026. The buyback programme runs from 1 September 2026 until no later than 31 December 2026, and it is executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5 and the Commi

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 4 SEPTEMBER 2026 at 9.00 EEST 102,000 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 102,000 A shares have been converted into 102,000 B shares. The conversion has been entered into the Trade Register on 4 September 2026. The total number of shares in Orion Corporation is 141,134,278 which, after the co

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE27 AUGUST 2026 at 13.00 EEST Orion Corporation to commence acquisition of own shares for its share-based incentive plans On 27 August 2026, the Board of Directors of Orion Corporation decided to commence acquisition of the Company’s own shares based on the authorisation granted by the Annual General Meeting held on 24 March 2026. According to the decision, up to 500,000 Class B shares of